Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Glenmede Trust Co. NA

Glenmede Trust Co. NA lifted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 28.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 487,131 shares of the biopharmaceutical company’s stock after acquiring an additional 109,283 shares during the period. Glenmede Trust Co. NA owned approximately 0.38% of Halozyme Therapeutics worth $27,883,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC grew its stake in shares of Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 254 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at approximately $33,000. Skandinaviska Enskilda Banken AB publ bought a new position in Halozyme Therapeutics during the second quarter worth $49,000. Toth Financial Advisory Corp acquired a new position in Halozyme Therapeutics in the third quarter worth $57,000. Finally, FSC Wealth Advisors LLC bought a new stake in Halozyme Therapeutics during the third quarter valued at $65,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $48.47 on Thursday. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53. The firm has a market capitalization of $6.17 billion, a PE ratio of 16.05, a P/E/G ratio of 0.43 and a beta of 1.29. The company’s 50 day simple moving average is $54.00 and its 200 day simple moving average is $53.71. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15.

Insider Activity

In other news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $59.09, for a total value of $590,900.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares in the company, valued at $39,988,802.96. This represents a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders have sold 60,000 shares of company stock worth $3,425,000. 2.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

HALO has been the topic of several research reports. Benchmark reiterated a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Morgan Stanley boosted their price target on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $68.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, November 20th. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Finally, TD Cowen raised their price target on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $61.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.